OncLive TV

Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma

November 22nd 2024

Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.

Dr Singer on Toxicities Associated With First-Line IO/TKI Regimens in RCC

November 22nd 2024

Adam E. Singer, MD, PhD, discusses the safety profiles of immuno-oncology/TKI regimens in first-line renal cell carcinoma.

Dr Reidy-Lagunes on the Evolving NET Treatment Paradigm

November 22nd 2024

Diane Reidy-Lagunes, MD, discusses key trials that have expanded the treatment paradigm for patients with neuroendocrine tumors.

Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer

November 22nd 2024

Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.

Dr Kalinsky on the Implications of DESTINY-Breast06 for T-DXd Use in HER2-Ultralow Breast Cancer

November 22nd 2024

Kevin Kalinsky, MD, MS, discusses the phase 3 DESTINY-Breast06 trial evaluating trastuzumab deruxtecan in HER2-expressing breast cancer.

Dr Ecker on the Role of CAPETEM in the Treatment of Pancreatic NETs

November 22nd 2024

Dr Janjigian on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma

November 22nd 2024

Yelena Y. Janjigian, MD, discusses the significance of the FDA approval of zolbetuximab plus chemotherapy for HER2–, CLDN18.2+ gastric/GEJ adenocarcinoma.

Dr Hochster on the Role of Cooperative Trials in Academic and Community Health Care Settings

November 21st 2024

Howard S. Hochster, MD, FACP, discusses the role of cooperative group clinical trials in bridging the gap between academic and community cancer centers.

Dr Strickler on the Role of Biomarker Testing in Pancreatic Cancer

November 21st 2024

John H. Strickler, MD, discusses the role of biomarker testing in metastatic pancreatic cancer.

Dr Smaglo on the Evolution of RAS-Targeted Therapies for Pancreatic Cancer

November 21st 2024

Brandon G. Smaglo, MD, FACP, discusses the ongoing research with RAS-targeted therapies for pancreatic cancer.

Dr Pobel on the Prognostic Value of Phenotypic and Genomic Characterization in De Novo mCSPC

November 20th 2024

Cedric Pobel, MD, discusses the potential prognostic value of phenotypic and genomic characterization of de novo mCSPC from the phase 3 PEACE-1 trial.

Dr O’Regan on Sequencing Considerations in Advanced HR+ Breast Cancer

November 20th 2024

Ruth O'Regan, MD, discusses considerations for sequencing strategies in advanced hormone receptor–positive breast cancer.

Dr Grunwald on Monitoring Risk Factors for Disease Progression in PV

November 20th 2024

Michael R. Grunwald, MD, discusses the importance of monitoring risk factors associated with disease progression in patients with polycythemia vera.

Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal Disease

November 20th 2024

Peter Forsyth, MD, discusses the design of a first-in-human phase 1 trial evaluating HER2/HER3–targeted intrathecal dendritic cells in leptomeningeal disease.

Dr Allan on Efforts to Clarify the Optimal Treatment Sequence in CLL

November 20th 2024

John N. Allan, MD, discusses ongoing efforts to address areas of uncertainty regarding the optimal sequencing strategy in CLL.

Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL

November 19th 2024

Kathleen A. Dorritie, MD, discusses 5-year of follow-up data from the CAPTIVATE trial in chronic lymphocytic leukemia and/or small lymphocytic lymphoma.

Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management

November 19th 2024

Minoo Battiwalla, MD, MS, discusses how emerging therapies contribute to the management of aggressive variants of follicular lymphoma.

Dr Moore on AEs Associated With ADC Treatment in Gynecologic Cancers

November 19th 2024

Kathleen N. Moore, MD, MS, discusses adverse effects associated with the use of antibody-drug conjugates for the treatment of gynecologic cancers.

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

November 19th 2024

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma

November 19th 2024

David R. Oveisi, MD, discusses the importance of clear communication with patients prior to administering CAR T-cell therapy for multiple myeloma.